<DOC>
	<DOCNO>NCT01502124</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial evaluate safety profile Norditropin® ( lyophilize somatropin ) Norditropin® cartridge ( liquid somatropin ) child growth hormone deficiency .</brief_summary>
	<brief_title>Safety Efficacy Somatropin Children With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Diagnosis short stature ( height maximum 2 standard deviation mean age gender ) inadequate growth deem secondary growth hormone deficiency ( GHD ) Naïve growth hormone therapy Known suspect allergy trial product relate product Growth retardation attributable cause GHD . Growth retardation attributable diabetes mellitus , inborn error metabolism , primary bone disease , chromosomal disorder disease genitourinary , cardiopulmonary , gastrointestinal central nervous system ; bone marrow transplantation syndrome know give short stature ( example : PraderWilli Syndrome , RussellSilver Syndrome , Turner Syndrome , Noonan Syndrome ) Intrauterine growth retardation : birth weight 3rd percentile , adjust gestational age Pregnancy intention become pregnant Breastfeeding Administration growthaltering medication</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>